BIOTECHNOLOGY RESEARCH FOR NERVOUS SYSTEM DISORDERS
BIOTECHNOLOGY RESEARCH FOR NERVOUS SYSTEM DISORDERS
BIOTECHNOLOGY RESEARCH FOR NERVOUS SYSTEM DISORDERS
HUXLEY GROUP OF WORLD-CLASS PROFESSIONALS
BOARD OF DIRECTORS
Bruce is a disruptive leader across a range of industries from tech to cannabis to global wellness. He has been the driving force behind the creation of multiple multi-billion-dollar global enterprises. Bruce Linton is the founder, former CEO, and Chairman of Canopy Growth Corporation. Bruce currently holds positions on the Board of Creso Pharma (ASX: CPH), Chairman of the Advisory Board for Red Light Holland Corp. and Chairman of Huxley Health Inc. He holds positions as Advisor with Celadon Pharmaceuticals and Above Foods.
Bruce is a board member of the Canadian Olympic foundation and an active member of The Ottawa Hospital Foundation, Campaign Executive Committee. Formerly, Bruce was a founding Board of Director, and Chairman of the Governance and Compensation Committee at Mind Medicine Inc (Nasdaq MNMD), and founding Executive Chairman of Gage Growth Corp., prior to being acquired by TerrAscend. Bruce was also Chairman and Chief Executive Officer of Collective Growth Corporation (SPAC) which went public in May 2020.
BRUCE LINTON
Co-Founder & Chairman
Fabian Monaco is the owner of Giumar Capital Inc., a boutique investment banking and advisory practice. Mr. Monaco is also the co-founder and former CEO of Gage Growth Corp. (“Gage”), which was acquired by TerrAscend Corp. for $500M+ in 2022. Mr. Monaco, along with the co-founders, grew Gage to a $100M revenue business, operating 15+ retail locations with over 350+ employees. Mr. Monaco is also a lawyer and brings a wealth of experience in capital raising and capital markets advisory. He has held various roles in large multi-national legal firms and investment banks, specializing in M&A advisory and financing transactions.
FABIAN MONACO
Board Member
John Di Girolamo is an experienced investor and entrepreneur with over twenty years of global business experience in public and private investments. His experience includes operational management, investment banking, strategic acquisitions and investments, international business development, and merchant banking across many sectors. John is currently the Managing Partner and Chief Compliance Officer of Liberty North Capital Corporation in Toronto. More recently, he has been involved in various transactions across several sectors, helping raise capital for his clients, providing advisory services, and overseeing the structuring of mergers and acquisitions. Mr. Di Girolamo has chaired seminars in partnership with other organizations, including the Toronto Stock Exchange, educating others on how to take companies public in Canada.
JOHN DiGIROLAMO
Board Member
EXECUTIVE TEAM
JARED RHINES
With over 30 years of pharmaceutical experience and has held leadership positions in the industry with a focus on international drug development and commercialization. He has proven success in commercializing products in multiple therapeutic areas in US and Canada, and establishing and leading local entities in Asia, Latin America, and Europe. His experience spans clinical research, regulatory affairs, sales, marketing, and market access in multiple therapeutic areas, including rare diseases, neurology, cardiology, and critical care.
Jared, along with 5 colleagues, founded INO Therapeutics, a company which was eventually acquired for $2.3b USD. He has extensive Canadian country management experience, including start-up, building and leading teams, operations, market access and pricing negotiations. In addition he served on the Board of Directors of IMC (Canada’s Pharmaceutical Association). Jared earned is undergraduate degree from the University of Pennsylvania and his Masters of Business Administration from Duke University's Fuqua School of Business.
Chief Executive Officer
GEORGE JACKOWSKI
Chief Science Officer
Dr. George Jackowski has significantly impacted the Healthcare/Biotech Sector over a 35-year career, founding 20 companies and assisting in another 10. He’s taken several of these companies to public markets in the US (NASDAQ, OTC) and Canada (TSX, CSE), creating over 1,000 high-tech jobs. His track record includes delivering valuations from tens of millions to over $350 million USD, providing seed investors with 3–10X returns within 18 months post-startup.
Dr. Jackowski has successfully cleared over 25 products through the US FDA, commercializing them globally, with revenues exceeding $10 billion USD. He has a significant track record in IP creation, patent litigation, and successful US patent issuances, with over 200 patents issued and filed. Notably, his patent for Cardiac Troponin immunoassays has generated over $500 million USD annually for over 20 years.
He co-founded a biotech company developing therapeutics against human cancer cell lines, which sold for over $190 million USD to Big Pharma. Dr. Jackowski has also completed over $100 million USD in licensing deals.Recognized for his contributions to Canadian Biotech and Pharmaceutical Industries, he received the Queen Elizabeth II Diamond Jubilee Medal and the 1996 MEDEC Award for Medical Achievement. Trained at the University of San Francisco and the University of Toronto, he has authored numerous publications and holds over 200 US patents.
PETER KAMPIAN
Chief Financial Officer
Peter Kampian is a seasoned executive with over two decades of financial expertise gained through various roles, including his tenure as the Chief Financial Officer of Algonquin Power and Utilities Corp., where he led and supported debt and equity capital raising initiatives, along with numerous acquisitions. Kampian also held the role of CFO at Mettrum Health Corp., which was later acquired by Canopy Growth Corp., and serves as CFO at Electryon Power Inc. and Huxley Health Inc. In addition to his executive roles, Kampian has served on several boards, such as Aduro Clean Technologies Inc., Harborside Inc., Greenbutts Inc., Red Pine Exploration Inc., and as a director at Origin House, a cannabis branding and distribution company based in California. Most recently, he has applied his expertise as the Chief Restructuring Officer for the Canadian cannabis companies PharmHouse Inc. and Muskoka Grown Limited.
JONATHAN SIMONE
PHD
EVP of R&D
ROHIT RAMCHANDANI DrPH, MPH
With over 20 years of experience designing, managing, implementing, evaluating and scaling complex health interventions around the world, Dr. Ramchandani is an award-winning researcher, innovator, advisor and business executive. As a Doctor of Public Health, he has led projects and programs responsible for saving thousands of lives. He holds faculty appointments at Johns Hopkins University and the University of Waterloo, is a Fellow of the Balsillie School of International Affairs and serves on the Board of Directors of the Jane Goodall Institute. He has published numerous academic papers, taught courses on, and is a recognized leader in the area of health innovation. His work has been the subject of books, documentaries, and case studies, receiving numerous accolades including the Financial Times/International Finance Corporation's Transformational Business Award in Health. An alumnus of the Governor General’s Candian Leadership Conference, he holds a Doctorate from the Johns Hopkins Bloomberg School of Public Health, an MPH from Boston University, and an honours BSc from the University of Waterloo.
Innovation
SANTINO BERNAUDO
Business Development
Santino Bernaudo is a serial entrepreneur with a keen eye for identifying new growth sector opportunities. Santino excels in introducing innovation to sectors traditionally resistant to change. Santino's career is marked by a series of successful ventures, demonstrating his ability to not only envision but also actualize transformative business models. Proven track record in the areas of M&A and capital raise , product development and international market penetration experience with leading brands.